| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 23023 |
| Drug | Mosunetuzumab |
| Brand | Lunsumio® |
| Indication | Mosunetuzumab (Lunsumio®) as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. |
| Assessment Process | |
| Rapid review commissioned | 27/04/2023 |
| Rapid review completed | 25/05/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mosunetuzumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/05/2023 |
| Pre-submission consultation with Applicant | 04/07/2023 |
